A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Prior treatment

• Have any prior diagnosis of diabetes mellitus, that is type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus, except gestational diabetes.
• Have any of the following cardiovascular conditions within 6 months prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure (CHF).
• Participants with hypertension who do not have well-controlled blood pressure (BP) (\>140/90 mmHg), regardless of antihypertensive treatment. Participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening.
• Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.

Other illness

• Have a history of New York Heart Association (NYHA) Functional Classification I-IV CHF.
• Have a history of acute or chronic pancreatitis.
  • Note: If the investigator anticipates a need to add antihypertensive medication during the study, the participant should not be included in the ambulatory blood pressure monitoring (ABPM) procedures.
  • CWMM:
• Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
• Have poorly controlled hypertension.
• Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
• Have a history of symptomatic gallbladder disease within the past 2 years.
• Have a lifetime history of suicide attempts.

Other

• W8M-MC-OXA1:

• W8M-MC-OXA1:
• Are males and females who agree to abide by the reproductive and contraceptive requirements
  • W8M-MC-CWMM:
• Have a BMI ≥27 kilograms per square meter (kg/m²)